Regeneron Pharmaceuticals (REGN) recently achieved a significant milestone with the FDA’s accelerated approval of Otarmeni, the first gene therapy for OTOF-related hearing loss. This breakthrough is noteworthy not only for its innovative approach—delivering a functional copy of the OTOF gene to improve hearing in patients—but also for its implications in the biotech sector, particularly as Regeneron will offer the treatment for free in the U.S. market.

While the decision to provide Otarmeni at no cost may seem counterintuitive, it reflects Regeneron’s strategic focus on enhancing its corporate image amidst public scrutiny over drug pricing. The market for OTOF-related hearing loss is small, with only 20 to 50 new cases diagnosed annually in the U.S., which limits the revenue potential. However, this initiative could pave the way for future gene therapies targeting larger patient populations, leveraging Regeneron’s acquisition of Decibel Therapeutics.

Investors should not expect immediate financial returns from Otarmeni, but Regeneron’s strong portfolio, including successful products like Dupixent and Eylea, alongside a robust pipeline, positions the company for continued growth. With recent revenue growth of 19% year-over-year, Regeneron remains a compelling option for investors looking for stability and innovation in the biotech space.

Source: fool.com